Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Európska únia - slovenčina - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedémy, dedičné - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Európska únia - slovenčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplazmy prsníkov - antineoplastické činidlá - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Európska únia - slovenčina - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinóm, šquamózna bunka - antineoplastické činidlá - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - kyselina zoledrónová - 87 - varia i

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - olmesartan medoxomil a amlodipín - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - olmesartan medoxomil a amlodipín - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - olmesartan medoxomil a amlodipín - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - ivabradín - 41 - cardiaca

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - ivabradín - 41 - cardiaca